Posted by: Salvatore J. Zambri, founding member and senior trial attorney.
ABC News reports that a new analysis by the Institute for Safe Medication Practices “says that there were 150 instances” where users of the smoking-cessation drug Chantix committed suicide “out of the nearly 600 delayed reports of severe issues noted in the study.” As a result, the FDA “wants the drug maker to resubmit thousands of records to get a clearer idea of just how widespread severe reactions to Chantix are, which also include vivid nightmares, depression and violent outbursts.”
I applaud the FDA in demanding Pfizer to release its records. Decisions to market drugs should be based principally on patient safety and health, not on profits. It would be a shame if people lost their lives as a result of using a drug after side-effects were concealed.
Do you have any questions about this post?
About the author:
Mr. Zambri is a Board-Certified Civil Trial Attorney and Past-President of the Trial Lawyers Association of Metropolitan Washington, D.C. The association has recently named him the ” 2011 Trial Lawyer of the Year“. He has also been acknowledged by Washingtonian magazine as a “Big Gun” and among the “top 1%” of all of the more than 80,000 lawyers in the Washington metropolitan area. The magazine also acknowledged him as “one of Washington’s best–most honest and effective lawyers” who specializes in medical malpractice matters, product liability claims, and serious automobile accident claims. Mr. Zambri was recently (2011 edition) acknowledged as one of the “Best Lawyers in America” by Best Lawyers, and has also been repeatedly named a “Super Lawyer” by Law and Politics magazine (2011)–a national publication that honors the top lawyers in the country.
Mr. Zambri is regularly asked to present seminars to lawyers and doctors, as well as both medical and law students concerning defective drugs, medication errors, medical malpractice litigation, and safety improvements.
If you have any questions about your legal rights, please email Mr. Zambri at [email protected]. You may also reach him at 202-822-1899.